As part of the important Drug Target Validation Service, CYGX is the sole pioneer in developing novel business structures to effectively combine leading edge biotechnology with traditional pharmacology through PharmaGenix, LLC, a joint enterprise with the Professional Compounding Centers of America, and their nearly 3,000 member compounding pharmacists.
It may well be that many previously incurable diseases will be cured through the gene therapy. CytoGenix, Inc. will play a vital role in this effort because of the insight of the company's leadership. CEO Malcolm Skolnick understands and agrees with an observation made long ago:
We know our ssDNA expression system works." said CEO Skolnick," The proof of concept phase is over. We are now ready to develop our broad-based technology into important therapeutics to eliminate or ameliorate specific disorders."
